Targeting Ligand Dependent and Ligand Independent Androgen Receptor Signaling in Prostate Cancer
Annual rept. 30 Sep 2013-29 Sep 2014
TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER
Pagination or Media Count:
We continue to make significant progress in our work with peptidomimetics targeting ligand-dependent and ligand-independent androgen receptor signaling in Prostate Cancer. We have further designed, created, tested and validated over a hundred analogues of our lead compound. We have overcome problems with solubility, off-target effects, toxicity and formulation. We have improved potency of our lead compounds, made some of them more selective for the interaction between the Androgen receptor and select coactivators and are now in the process of optimizing these compounds prior to testing in animal experiments.
- Medicine and Medical Research